In late December, rumors regarding a dangerous virus that originated in a seafood market in Wuhan, China started spreading across the world. At the time, all we knew was that the virus resembled the severe acute respiratory syndrome, better known as SARS, and that it was aggressive and deadly.
After a series of global epidemics, Don Berry has spent the past several years preparing for a serious pandemic that would be caused by yet another viral pathogen.
Experts in infectious diseases and investors on Wall Street are honing in on two potential treatments for COVID-19: interleukin inhibitors and remdesivir.
News coverage of the COVID-19 pandemic in New York has lent urgency to social distancing efforts in San Antonio and South Texas, likely flattening the curve.
J. Alan Diehl was named deputy director and chief operating officer of the Case Comprehensive Cancer Center.
Andres F. Correa will join Fox Chase Cancer Center as an assistant professor in the Department of Surgery in the Urologic Oncology Division starting May 4.
Esther Welkowsky was named vice president of Clinical Operations at Elicio Therapeutics, a next generation immuno-oncology company. Welkowsky has managed clinical operations teams for oncology clinical trials and was most recently executive director of Clinical Operations at Allogene.
FDA has approved Koselugo (selumetinib) for the treatment of pediatric patients, two years and older, with neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves.
FDA has approved mitomycin (Jelmyto) for adult patients with low-grade upper tract urothelial cancer.
Merck April 15 introduced Ontruzant(trastuzumab-dttb), a biosimilar of the reference biologic medicine Herceptin, to the U.S. Ontruzant is available in both 150 mg single-dose vials and 420 mg multiple-dose vials.
